NGS and TME for Evidence-based Treatment of Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The tumor tissue of patients with pancreatic cancer will be submitted to next-generation sequencing (NGS) and these data will be evaluated with an oncology treatment decision support (TDS) software tool that is a medicinal product class 1 (CE-marked). This software will make evidence-based suggestions for drugs likely to be effective, ineffective, or toxic (FDA approved biomarkers). For patients fit for second-line therapy, the resulting recommendations will be judged by the tumor board.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NCT06574620

Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Ductal Adenocarcinoma Borderline Resectable Pancreatic Ductal Adenocarcinoma +1 more

RECRUITING NA

Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection

NCT02750657

Carcinoma, Pancreatic Ductal

COMPLETED

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

NCT02869802

Cancer Pancreatic Cancer

RECRUITING

Predicting Effective Therapy in Pancreatic Cancer

NCT03033927

Pancreatic Cancer Pancreatic Adenocarcinoma

ACTIVE_NOT_RECRUITING

Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines

NCT04379960

The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tumor tissue of patients (surgical resection, biopsy) will be used for SWEDAC-certified DNA extraction and NGS. Pseudonymised sequencing data will be fed into a TDS software tool (TreatmentMAP™, Molecular Health) and based on published evidence, suggestions will be made, graded into NCCN categories of approved drugs in indication or otherwise, clinical evidence or experimental. Same with anticipated inefficacy. In addition, FDA-approved biomarkers for toxicity will be analysed. This information is taken to the tumor board for making a decision whether this information is useful and eventually to recommend a treatment for a given patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Ductal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NGS

Next generation sequencing

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age ≥ 18 years up to 75 years
* Patient willing and able to provide informed consent
* TreatmentMAP™ NGS/TME is ordered by the tumor board (MDT) under routine clinical practice
* Diagnosis of a locally advanced, inoperable or metastatic pancreatic carcinoma, clinically and histologically verified according to the currently prevailing standards.
* Patient received first line therapy according to applicable guidelines and/or standards (SoC)
* Sufficient testing material available (e.g. tumor biopsy) to allow NGS/TME NGS panel testing.

Exclusion Criteria

* Patients with ongoing systemic infection,
* Patients with immunodeficiency,
* Patients with severe cardiovascular and pulmonary morbidity that might interfere with or preclude further systemic anticancer treatment,
* Patients on full therapeutic anticoagulation.
* Patients who, due to their clinical status, are not eligible for further systemic anticancer therapy (chemotherapy, immunotherapy etc.)
* Patients who, due to their disease status are in need of immediate therapy and cannot wait for the result of the NGS/TME process.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No